Skip To Main Content
Clinics Essen-Mitte on Muck Rack

Clinics Essen-Mitte

As seen in: Molecular Cancer, The Lancet
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Clinics

Contact Clinics, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial

|
By Sherko Kuemmel, Clinics Essen-Mitte, Monika Graeser, Peter Schmid
| The Lancet Verified
Get full text access Log in, subscribe or purchase for full access. References 1. Baselga, J ∙ Bradbury, I ∙ Eidtmann, H ∙ et al., the NeoALTTO Study Team Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet. 2012; 379:633-640 2. Robidoux, A ∙ Tang, G ∙ Rastogi, P ∙ et al.
Open in Who Shared Issue with article?

Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial | Molecular Cancer | Full Text

|
By zu Eulenburg, Hans Heinrich, Clinics Cologne, Clinics Essen-Mitte
| Molecular Cancer Verified
References Cortazar P, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72. Article PubMed Google Scholar Schmid P, et al. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. N Engl J Med. 2024;391(21):1981–91. Article CAS PubMed Google Scholar Gluz O, et al.
Open in Who Shared Issue with article?

Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial | Molecular Cancer

|
By zu Eulenburg, Hans Heinrich, Clinics Cologne, Clinics Essen-Mitte
| link.springer.com
Abstract Anthracycline-containing neoadjuvant chemotherapy (NACT) is the standard treatment for early triple-negative breast cancer (eTNBC); however, it is associated with substantial toxicity. We performed whole transcriptome profiling of baseline tumor biopsies to identify gene networks predictive and prognostic for pathological complete response (pCR) and survival after de-escalated, anthracycline-free NACT in the WSG-ADAPT-TN trial (NCT01815242).
Open in Who Shared Issue with article?
See all 4 articles